Phase II longitudinal trial of PI-2620 in patients with mild cognitive impairment (MCI) and mild to moderate Alzheimer's-disease
Latest Information Update: 24 Sep 2019
At a glance
- Drugs PI 2620 (Primary)
- Indications Alzheimer's disease; Mild cognitive impairment
- Focus Diagnostic use
- 24 Sep 2019 New trial record
- 17 Sep 2019 According to an AC Immune media release, data from this trial is intended to be used for obtaining regulatory approval in the U.S. and Europe.
- 17 Sep 2019 According to an AC Immune media release, it has received a milestone payment from its partner Life Molecular Imaging in connection with the initiation of this study.